memantine in bradykinesia of parkinson

Evaluation the effect of memantine on bradykinesia in parkinson

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190207042651N1

Enrollment

Registered

2019-04-09

Start date

2018-01-20

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Diseases. Parkinson's disease

Interventions

Intervention 1: Intervention group: They are treated with routine Arthanes, Amantadine, Selegiline and Parkin C with Take Memantine 10 mg tablet overnight (one time per night). Memantine will be used

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe Parkinson's disease are incapable with maximal dose of levodopa Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Affected to underlying diseases Under treatment for nervous disease Patients who are reluctant to participate in the study

Design outcomes

Primary

Measure	Time frame
Bradykinesia. Timepoint: Before treatment, with a 6 month's interval in one year from starting treatment. Method of measurement: Evaluation status of tremor variation, number of steps in 100 meters, number of steps in 360 degrees, directional change and evaluation of finger taping performance.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKeyvan Qasami

Arak University of Medical Sciences

Keyvanqasami@yahoo.com+98 86 3313 5075

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026